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etter to the Editoralignant  forms  of  Mediterranean  spotted  fever:
dog tick Rhipicephalus sanguineus,  and human contact with theisk factors  for  fatal  outcomes
ear Editor,
s a result of globalization and growing tourism, imported
ases of Mediterranean spotted fever (MSF) were reported
n many  non-endemic countries and regions.1 Molecular
nstruments such as PCR and sequencing have identiﬁed the
Table 1 – Mediterranean spotted fever malignant forms: risk fac
Indicators MSF lethal
cases n = 19
(n/%)
MSF sur
n = 36
(n/%
Age >45 years 17/19
89.47
16/
44.
More than 6 days to hospital admission 17/19
89.47
12/
33.
Pre-morbid underlying conditions 15/19
78.94
2/3
5.5
Tick bite (Tache noire) 17/19
89.47
24/
66.
Sever disturbances in acid–base balance 13/19
68.42
4/3
11.
Failure to start or to complete appropriate
antibiotic treatment
11/19
57.89
4/3
11.
Lung involvement (interstitial pneumonia) 13/19
68.42
16/
44.
Acute renal failure 16/19
84.21
14/
38.
Gastrointestinal bleeding 6/19
31.57
2/3
5.5
Liver involvement (ALT/AST high levels) 16/19
84.21
35/
97.
Liver involvement (Jaundice) 11/19
57.89
24/
66.
Pancreatic involvement 4/19
21.05
1/3
2.7
Myocardial involvement 8/19
42.10
8/3
22.
CNS involvement: (Mental confusion –
“Typhus state”)
19/19
100
30/
83.
CNS involvement: Encephalitis (delirium,
seizures, stupor, coma)
12/19
63.15
12/
33.
CI, conﬁdence interval; MSF, Mediterranean spotted fever.etiologic agent – Rickettsia conorii subsp. conorii,  strain Malish
Seven.2 Rickettsiae are transmitted to humans by the bite of thetors for fatal outcomes.
vivors
)
Two tailed p Odds ratio 95% CI
Fisher’s exact test
36
44
=0.001  10.625 2.13–52.95
36
33
<0.0001  17.00 3.36–86.03
6
5
<0.0001  63.75 10.5–386.9
36
66
=0.103  4.250 0.84–21.50
6
11
<0.0001  17.333 4.19–71.73
6
11
=0.0004  11.00 2.76–43.82
36
44
=0.15  2.708 0.84–8.725
36
88
=0.001  8.381 2.06–34.12
6
5
=0.01  7.846 1.40–43.97
36
22
=0.11  0.152 0.014–1.58
36
66
=0.58  0.687 0.218–2.16
6
7
=0.04  9.333 0.96–90.69
6
22
=0.210  2.545 0.76–8.478
36
33
=0.08  1.719 0.558–5.29
36
33
=0.04  3.429 1.07–10.96
tick intermediate hosts – domestic and stray dogs, is an impor-
tant epidemiological determinant. The main clinical signs and
symptoms of MSF are: a skin eschar (tache noire) at the site of
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tick bite, fever and ﬂu-like manifestations such as headache,
adynamia, anorexia, myalgia, etc., emerging 3–5 days before
the onset of papular or maculopapular rash over the trunk
and extremities, involving the hands and feet. In the past
overlooked as a serious disease, at present it is known that
MSF  was wrongly considered a benign condition. In the early
1980s, D. Raoult reported a patient with a fatal outcome due to
MSF  and used the term “malignant” for the most severe forms
of the disease.3 Since MSF  has spread intensively in many
European countries, a number of malignant, including fatal,
cases have been described. The mortality rate reached 54.5%
in hospitalized patients with neurological manifestations and
multiorgan involvement.4,5
The purpose of this study was to outline the risk factors
contributing to the fatal outcome in patients with malig-
nant MSF.  Fifty-ﬁve patients (30 men  and 25 women) with
malignant forms of MSF  were included in the study. They
were divided in two groups: Group I comprised 19 fatalities
(34.54%) with mean age of 59.55 ± 4.09 years; Group II com-
prised 36 survivors (65.45%) with mean age of 47.22 ± 5.81
years. MSF  was conﬁrmed by the indirect immunoﬂuores-
cent assay (IFA), with at least a fourfold increase in the
antibody titer to a speciﬁc R. conorii antigen (IFA test Rick-
ettsia conori – Spot IF, BioMerieux, Marcy  L’Etoile, France). IgG
titers of ≥128 and/or IgM titers of >64 were considered indica-
tive of acute infection. Based on our data, the risk factors
for mortality in malignant MSF  patients were: advanced age,
delayed hospital admission, underlying chronic diseases, fail-
ure to start or to complete appropriate antibiotic treatment,
and severe involvement of multiple organ systems, especially
CNS (Table 1). Risk complications for death according to our
data were: encephalitis with brain edema, acute respiratory
distress syndrome and non-cardiogenic lung swelling, gas-
trointestinal bleeding, hemorrhagic-necrotizing pancreatitis,
and acute renal failure. Laboratory factors associated with
fatality were: leukocytosis with marked shift to the left; very
high serum urea and creatinine levels; low levels of ﬁbrino-
gen and prolongation of thrombin time; and serious acid–base
balance disturbance.
Long time overlooked as a serious disease, at present, it is
known that MSF  is wrongly considered a benign condition. In
this report we  managed to identify risk factors associated with
mortality in malignant forms of MSF.  This approach is justiﬁed
as the diagnosis in such cases is frequently a problem. We  hope 1 6;2  0(5):511–512
that our research would contribute to prompt diagnosis and
prompt adequate treatment.
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